Ensign Peak Advisors
AVIR icon

Ensign Peak Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Ensign Peak Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-84,030
Closed -$314K – 1756
2023
Q2 		$314K Buy
84,030
+15,550
+23% +$58.2K ﹤0.01% 1708
2023
Q1 		$229K Buy
68,480
+19,500
+40% +$79.1K ﹤0.01% 1735
2022
Q4 		$236K Buy
48,980
+19,200
+64% +$97.1K ﹤0.01% 1733
2022
Q3 		$169K Hold
29,780
– – ﹤0.01% 1932
2022
Q2 		$211K Hold
29,780
– – ﹤0.01% 1778
2022
Q1 		$215K Hold
29,780
– – ﹤0.01% 1861
2021
Q4 		$266K Buy
+29,780
New +$464K ﹤0.01% 1853

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ensign Peak Advisors's AVIR Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 84,030 shares — an estimated $314K sold.

Ensign Peak Advisors first reported a position in AVIR in Q4 2021 and held it in 7 quarters. The position peaked at $314K in Q2 2023. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • Ensign Peak Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 84,030 Atea Pharmaceuticals shares in Q3 2023, an estimated $314K.
  • Ensign Peak Advisors first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Ensign Peak Advisors's Atea Pharmaceuticals position peaked at $314K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.